Cart
sales@molnova.com
Amino Tadalafil
CAS No. 385769-84-6
Amino Tadalafil( —— )
Catalog No. M20955 CAS No. 385769-84-6
Amino tadalafil is a potent phosphodiesterase 5 (PDE5) inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 10MG | 33 | In Stock |
|
| 25MG | 65 | In Stock |
|
| 50MG | 91 | In Stock |
|
| 100MG | 145 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAmino Tadalafil
-
NoteResearch use only, not for human use.
-
Brief DescriptionAmino tadalafil is a potent phosphodiesterase 5 (PDE5) inhibitor.
-
DescriptionAmino tadalafil is a potent phosphodiesterase 5 (PDE5) inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE5
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number385769-84-6
-
Formula Weight390.39
-
Molecular FormulaC21H18N4O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESNN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O
-
Chemical Name2-Amino-6(R)-benzo[13]dioxol-5-yl-23671212a(R)-hexahydro-pyrazino[1'2':16]pyrido[34-b]indole-14-dione
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Hadwiger M E Trehy M L Ye W et al. Identification of amino-tadalafil and rimonabant in electronic cigarette products using high pressure liquid chromatography with diode array and tandem mass spectrometric detection[J]. Journal of Chromatography A 2010 1217(48):7547-7555.
molnova catalog
related products
-
Aminophylline
Aminophylline is a competitive nonselective phosphodiesterase inhibitor that is used to treat airway obstruction from asthma or COPD.
-
LJI308
LJI308 is a potent, and pan-RSK (p90 ribosomal S6 kinase) inhibitor with IC50 of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively.
-
Ensifentrine
Ensifentrine is a PDE3/4 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.
